Loading...
Keywords
Last Name
Institution

Connection

Search Results to Alan S. Gamis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Gamis, Alan

PropertyValue
keywords AML
research overview Dr. Gamis' research expertise is in the design and development of multi-institutional clinical trials in childhood cancer, specifically in AML. He is a board certified Pediatric Hematologist/Oncologist and continue to care for patients with cancer in a large children's cancer center. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. He has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the phase III trial COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the present. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time we designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original PI of a clinical core center of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008. Locally, as the Director of the Children's Mercy Cancer Center, Dr. Gamis oversee all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center.

One or more keywords matched the following items that are connected to Gamis, Alan

Item TypeName
Academic Article Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
Academic Article Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
Academic Article Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group.
Academic Article Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Academic Article Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
Academic Article Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Academic Article Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
Academic Article The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
Academic Article Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
Academic Article Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
Academic Article NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
Academic Article Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML?
Academic Article Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
Academic Article CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Academic Article Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
Academic Article miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Academic Article Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group.
Academic Article Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group.
Academic Article Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.
Academic Article CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
Academic Article Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
Academic Article Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Academic Article CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Academic Article Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Academic Article Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.
Academic Article Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA.
Academic Article A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Search Criteria
  • AML